BACKGROUND: Patients with lung cancer with mutations in EGF receptor (EGFR) tyrosine kinase have improved prognosis when treated with EGFR inhibitors. We hypothesized that EGFR mutations may be related to residential radon or passive tobacco smoke. METHODS: This hypothesis was investigated by analyzing EGFR mutations in 70 lung tumors from a population of never and long-term former female smokers from Missouri with detailed exposure assessments. The relationship with passive smoking was also examined in never-smoking female lung cancer cases from the Mayo clinic. RESULTS: Overall, the frequency of EGFR mutation was 41% [95% confidence interval (CI), 32%-49%]. Neither radon nor passive-smoking exposure was consistently associated with EGFR mutations in lung tumors. CONCLUSIONS: The results suggest that EGFR mutations are common in female, never-smoking lung cancer cases from the United States, and EGFR mutations are unlikely due to exposure to radon or passive smoking.
BACKGROUND:Patients with lung cancer with mutations in EGF receptor (EGFR) tyrosine kinase have improved prognosis when treated with EGFR inhibitors. We hypothesized that EGFR mutations may be related to residential radon or passive tobacco smoke. METHODS: This hypothesis was investigated by analyzing EGFR mutations in 70 lung tumors from a population of never and long-term former female smokers from Missouri with detailed exposure assessments. The relationship with passive smoking was also examined in never-smoking female lung cancer cases from the Mayo clinic. RESULTS: Overall, the frequency of EGFR mutation was 41% [95% confidence interval (CI), 32%-49%]. Neither radon nor passive-smoking exposure was consistently associated with EGFR mutations in lung tumors. CONCLUSIONS: The results suggest that EGFR mutations are common in female, never-smoking lung cancer cases from the United States, and EGFR mutations are unlikely due to exposure to radon or passive smoking.
Authors: Jonathan M Samet; Erika Avila-Tang; Paolo Boffetta; Lindsay M Hannan; Susan Olivo-Marston; Michael J Thun; Charles M Rudin Journal: Clin Cancer Res Date: 2009-09-15 Impact factor: 12.531
Authors: P Yang; K A Wentzlaff; J A Katzmann; R S Marks; M S Allen; T G Lesnick; N M Lindor; J L Myers; E Wiegert; D E Midthun; S N Thibodeau; M J Krowka Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-05 Impact factor: 4.254
Authors: K H Vähäkangas; W P Bennett; K Castrén; J A Welsh; M A Khan; B Blömeke; M C Alavanja; C C Harris Journal: Cancer Res Date: 2001-06-01 Impact factor: 12.701
Authors: Young Joo Lee; Byoung Chul Cho; Sun Ha Jee; Jin Wook Moon; Se Kyu Kim; Joon Chang; Kyung Young Chung; In Kyu Park; Sung Ho Choi; Joo-Hang Kim Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: H Dean Hosgood; William Pao; Nathaniel Rothman; Wei Hu; Yumei Helen Pan; Kyle Kuchinsky; Kirk D Jones; Jun Xu; Roel Vermeulen; Jeff Simko; Qing Lan Journal: Respir Med Date: 2013-09-03 Impact factor: 3.415